Abstract
Subcutaneous Interferon-beta (IFN-beta) injections for the treatment of multiple sclerosis (MS) frequently cause inflammatory injection site reactions. To study the role of chemokines we obtained skin biopsies from 7 MS patients 24 h after injection. At the IFN-beta but not at the contralateral placebo injection sites, we observed strong IP-10/CXCL10 and moderate MCP-1/CCL2 expression associated with extensive perivascular, highly CXCR3-positive T cell and macrophage infiltrates. Primary human skin cells displayed a comparable pattern of chemokine induction after stimulation with IFN-beta in vitro. IFN-beta may therefore trigger inflammatory skin reactions through local chemokine induction followed by rapid immune cell extravasation.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antigens, CD / metabolism
-
Biopsy
-
Cells, Cultured
-
Chemokines / genetics
-
Chemokines / metabolism
-
Cytokines / genetics
-
Cytokines / metabolism
-
Cytokines / pharmacology
-
Dose-Response Relationship, Drug
-
Electrophoretic Mobility Shift Assay / methods
-
Enzyme-Linked Immunosorbent Assay / methods
-
Female
-
Gene Expression Regulation / drug effects*
-
Gene Expression Regulation / physiology
-
Humans
-
Immunohistochemistry / methods
-
In Situ Hybridization / methods
-
Injections, Subcutaneous / methods
-
Interferon-beta / therapeutic use*
-
Male
-
Multiple Sclerosis / drug therapy*
-
Multiple Sclerosis / pathology
-
Multiple Sclerosis / physiopathology
-
Skin / drug effects*
-
Skin / pathology
Substances
-
Antigens, CD
-
Chemokines
-
Cytokines
-
Interferon-beta